Article Type
Changed
Fri, 01/04/2019 - 11:11
Display Headline
Re-personalizing precision medicine: is there a role for patient-reported outcomes?

In the opinion of most, precision medicine is the future of cancer therapeutics. By producing response rates well into double digits, and substantially extending progression-free and overall survival, the molecular testing of tumors to select optimal treatment may be a way to justify the high cost of new and emerging therapeutics. The road to this future will likely be long and winding, however, with a string of incremental successes amid inevitable disappointments. Our patients will walk this road with us, agreeing to testing and treatment when those tests come back positive for an eligible mutation.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(8)
Publications
Topics
Page Number
275-277
Legacy Keywords
precision medicine, personalized medicine, patient-reported outcomes, PRO, Molecular Analysis for Therapy Choice, MATCH, quality of life, QoL, genetic testing
Sections
Article PDF
Article PDF

In the opinion of most, precision medicine is the future of cancer therapeutics. By producing response rates well into double digits, and substantially extending progression-free and overall survival, the molecular testing of tumors to select optimal treatment may be a way to justify the high cost of new and emerging therapeutics. The road to this future will likely be long and winding, however, with a string of incremental successes amid inevitable disappointments. Our patients will walk this road with us, agreeing to testing and treatment when those tests come back positive for an eligible mutation.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

In the opinion of most, precision medicine is the future of cancer therapeutics. By producing response rates well into double digits, and substantially extending progression-free and overall survival, the molecular testing of tumors to select optimal treatment may be a way to justify the high cost of new and emerging therapeutics. The road to this future will likely be long and winding, however, with a string of incremental successes amid inevitable disappointments. Our patients will walk this road with us, agreeing to testing and treatment when those tests come back positive for an eligible mutation.

 

Click on the PDF icon at the top of this introduction to read the full article.

 

Issue
The Journal of Community and Supportive Oncology - 13(8)
Issue
The Journal of Community and Supportive Oncology - 13(8)
Page Number
275-277
Page Number
275-277
Publications
Publications
Topics
Article Type
Display Headline
Re-personalizing precision medicine: is there a role for patient-reported outcomes?
Display Headline
Re-personalizing precision medicine: is there a role for patient-reported outcomes?
Legacy Keywords
precision medicine, personalized medicine, patient-reported outcomes, PRO, Molecular Analysis for Therapy Choice, MATCH, quality of life, QoL, genetic testing
Legacy Keywords
precision medicine, personalized medicine, patient-reported outcomes, PRO, Molecular Analysis for Therapy Choice, MATCH, quality of life, QoL, genetic testing
Sections
Citation Override
JCSO 2015;13: 275-277
Disallow All Ads
Alternative CME
Article PDF Media